Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    The impact of COVID-19 MESHD in diabetic kidney disease MESHD kidney disease and chronic HP chronic kidney disease MESHD: A population-based study

    Authors: Juan Alonso Leon-Abarca; Roha Saeed Memon; Bahar Rehan; Maimoona Iftikhar; Antara Chatterjee; Andrés Gonzalez-Guerra; Emilio Camafeita; Mariya Lytvyn; María Isabel Guillén; David Sanz-Rosa; Daniel Martín-Pérez; Cristina Sanchez-Ramos; Ricardo Garcia; Juan Antonio Bernal; Sijia Tao; Tristan R Horton; Elizabeth N Beagle; Ernestine A Mahar; Michelle YH Lee; Joyce Cohen; Sherrie Jean; Jennifer S Wood; Fawn Connor-Stroud; Rachelle L Stammen; Olivia M Delmas; Shelly Wang; Kimberly A Cooney; Michael N Sayegh; Lanfang Wang; Daniela Weiskopf; Peter D Filev; Jesse Waggoner; Anne Piantadosi; Sudhir P Kasturi; Hilmi Al-Shakhshir; Susan P Ribeiro; Rafick P Sekaly; Rebecca D Levit; Jacob D Estes; Thomas H Vanderford; Raymond F Schinazi; Steven E Bosinger; Mirko Paiardini

    doi:10.1101/2020.09.12.20193235 Date: 2020-09-16 Source: medRxiv

    Background: The spectrum of pre-existing renal disease MESHD is known as a risk factor for severe COVID-19 MESHD outcomes. However, little is known about the impact of COVID-19 MESHD on patients with diabetic nephropathy MESHD nephropathy HP in comparison to patients with chronic kidney disease MESHD chronic kidney disease HP. Methods: We used the Mexican Open Registry of COVID-19 MESHD patients 11 to analyze anonymized records of those who had symptoms related to COVID-19 MESHD to analyze the rates of SARS-CoV-2 infection MESHD, development of COVID-19 MESHD pneumonia HP pneumonia MESHD, admission, intubation, Intensive Care Unit admission and mortality. Robust Poisson regression was used to relate sex and age TRANS to each of the six outcomes and find adjusted prevalences SERO and adjusted prevalence SERO ratios. Also, binomial regression models were performed for those outcomes that had significant results to generate probability plots to perform a fine analysis of the results obtained along age TRANS as a continuous variable. Results: The adjusted prevalence SERO analysis revealed that that there was a a 87.9% excess probability of developing COVID-19 MESHD pneumonia HP pneumonia MESHD in patients with diabetic nephropathy MESHD nephropathy HP, a 5% excess probability of being admitted, a 101.7% excess probability of intubation and a 20.8% excess probability of a fatal outcome due to COVID-19 MESHD pneumonia HP pneumonia MESHD in comparison to CKD patients (p<0.01). Conclusions: Patients with diabetic nephropathy MESHD nephropathy HP had nearly a twofold rate of COVID-19 MESHD pneumonia HP pneumonia MESHD, a higher probability of admission, a twofold probability of intubation and a higher chance of death once admitted compared to patients with chronic kidney disease MESHD chronic kidney disease HP alone. Also, both diseases had higher COVID-19 MESHD pneumonia MESHD pneumonia HP rates, intubation rates and case-fatality rates compared to the overall population. Keywords: COVID-19 MESHD, SARS-CoV-2, Chronic Kidney Disease MESHD Chronic Kidney Disease HP, diabetic nephropathy MESHD nephropathy HP

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.